PTC Therapeutics, Inc. - Common Stock (PTCT)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 1, 2026Investment Snapshot
- Trading 3,341% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -36,432.6%
- Revenue growing at 115% annually
PTC Therapeutics, Inc. - Common Stock (PTCT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $5.6 billion . Key value metrics: P/E ratio 7.9, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
PTC Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
PTC Therapeutics, Inc. - Common Stock (PTCT) is currently trading 3,341% above its Graham Number of $1.98, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 7.9x.
On financial health, PTCT shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -36,432.6% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 196.03.
StockPik's composite Value Score for PTCT is 84/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PTCT shows revenue growing at 115% year-over-year, with earnings growing at 288%.